CN105949335A - 一种具有抗血小板聚集活性的寡糖类组分及其制备方法 - Google Patents
一种具有抗血小板聚集活性的寡糖类组分及其制备方法 Download PDFInfo
- Publication number
- CN105949335A CN105949335A CN201610272887.9A CN201610272887A CN105949335A CN 105949335 A CN105949335 A CN 105949335A CN 201610272887 A CN201610272887 A CN 201610272887A CN 105949335 A CN105949335 A CN 105949335A
- Authority
- CN
- China
- Prior art keywords
- oligosaccharide
- column
- platelet aggregation
- kind component
- oligosaccharide kind
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 70
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 70
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title claims abstract description 24
- 239000003146 anticoagulant agent Substances 0.000 title claims abstract description 5
- 230000000702 anti-platelet effect Effects 0.000 title claims abstract 4
- 230000000694 effects Effects 0.000 title abstract description 12
- 238000002360 preparation method Methods 0.000 title abstract description 11
- 102000008186 Collagen Human genes 0.000 claims abstract description 8
- 108010035532 Collagen Proteins 0.000 claims abstract description 8
- 229920001436 collagen Polymers 0.000 claims abstract description 8
- 239000008523 shuxuetong Substances 0.000 claims abstract description 8
- 239000002243 precursor Substances 0.000 claims abstract description 6
- 239000002994 raw material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 238000005349 anion exchange Methods 0.000 claims description 12
- 239000003480 eluent Substances 0.000 claims description 11
- 229920005654 Sephadex Polymers 0.000 claims description 10
- 239000012507 Sephadex™ Substances 0.000 claims description 10
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 229930182830 galactose Natural products 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 150000002772 monosaccharides Chemical group 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 238000001556 precipitation Methods 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- 238000004440 column chromatography Methods 0.000 claims description 3
- 230000007717 exclusion Effects 0.000 claims description 3
- 239000002808 molecular sieve Substances 0.000 claims description 3
- 238000002203 pretreatment Methods 0.000 claims description 3
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 2
- 230000002776 aggregation Effects 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 230000006698 induction Effects 0.000 claims description 2
- -1 monosaccharide units Carbohydrate Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 13
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 229940079593 drug Drugs 0.000 abstract description 5
- 239000007924 injection Substances 0.000 abstract description 4
- 238000002347 injection Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 4
- 238000013176 antiplatelet therapy Methods 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 238000007385 chemical modification Methods 0.000 abstract description 2
- 238000000926 separation method Methods 0.000 abstract description 2
- 230000009466 transformation Effects 0.000 abstract description 2
- 241000545744 Hirudinea Species 0.000 abstract 1
- 241000243684 Lumbricus Species 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000001483 monosaccharide substituent group Chemical group 0.000 abstract 1
- 238000006116 polymerization reaction Methods 0.000 abstract 1
- 238000007670 refining Methods 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 23
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 10
- 239000013558 reference substance Substances 0.000 description 10
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 8
- 229960004756 ethanol Drugs 0.000 description 8
- 229960001031 glucose Drugs 0.000 description 8
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 150000004676 glycans Chemical class 0.000 description 7
- 229920001282 polysaccharide Polymers 0.000 description 7
- 239000005017 polysaccharide Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 208000007536 Thrombosis Diseases 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 238000001212 derivatisation Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 241000237636 Pheretima Species 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000237903 Hirudo Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960001138 acetylsalicylic acid Drugs 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 210000004623 platelet-rich plasma Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 description 1
- OAGSFHDUINSAMQ-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;sodium;hydrate Chemical compound O.[Na].OC(=O)CC(O)(C(O)=O)CC(O)=O OAGSFHDUINSAMQ-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 208000014604 Specific Language disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000001435 Thromboembolism Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- GZCGUPFRVQAUEE-KVTDHHQDSA-N aldehydo-D-mannose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O GZCGUPFRVQAUEE-KVTDHHQDSA-N 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- QELUYTUMUWHWMC-UHFFFAOYSA-N edaravone Chemical compound O=C1CC(C)=NN1C1=CC=CC=C1 QELUYTUMUWHWMC-UHFFFAOYSA-N 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229960002528 ticagrelor Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001195 ultra high performance liquid chromatography Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/04—Disaccharides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
- C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Materials Engineering (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Sustainable Development (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Time(min) | A% | B% |
0 | 95 | 5 |
2 | 92 | 8 |
13.34 | 70 | 30 |
15 | 40 | 60 |
16 | 20 | 80 |
18.67 | 20 | 80 |
19.33 | 95 | 5 |
21.67 | 95 | 5 |
样品 | 终浓度 | N | 血小板最大聚集率(%) | 抑制率(%) |
生理盐水 | - | 10 | 60.3±9.6 | - |
替格瑞洛 | 0.8μM/L | 10 | 35.8±3.6*** | 40.7 |
寡糖 | 4mg/mL | 10 | 4.6±4.2*** | 92.3 |
寡糖 | 2.3mg/mL | 10 | 34.5±3.5*** | 42.8 |
寡糖 | 1.33mg/mL | 10 | 50.1±5.7* | 16.9 |
样品 | 终浓度 | N | 血小板最大聚集率(%) | 抑制率(%) |
生理盐水 | - | 10 | 65.5±3.6 | - |
阿斯匹林 | 0.05mM/L | 10 | 18.4±2.6*** | 72 |
寡糖 | 5mg/mL | 10 | 13.4±4.2*** | 79.5 |
寡糖 | 3.5mg/mL | 10 | 35.1±2.6*** | 46.4 |
寡糖 | 2mg/mL | 10 | 44.8±3.0** | 31.6 |
Claims (11)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2015110092786 | 2015-12-31 | ||
CN201511009278 | 2015-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105949335A true CN105949335A (zh) | 2016-09-21 |
CN105949335B CN105949335B (zh) | 2018-02-09 |
Family
ID=56915967
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610272887.9A Active CN105949335B (zh) | 2015-12-31 | 2016-04-29 | 一种具有抗血小板聚集活性的寡糖类组分及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105949335B (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106674367A (zh) * | 2016-12-14 | 2017-05-17 | 烟台东诚药业集团股份有限公司 | 一种纯化制备低聚异麦芽糖的方法以及应用 |
CN109270176A (zh) * | 2018-08-22 | 2019-01-25 | 中国农业科学院农产品加工研究所 | 羊乳寡糖测定方法 |
WO2022067773A1 (zh) * | 2020-09-30 | 2022-04-07 | 牡丹江友搏药业有限责任公司 | 一种活性多肽及其应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103592303A (zh) * | 2013-11-25 | 2014-02-19 | 牡丹江友搏药业股份有限公司 | 一种疏血通注射液的抗凝血酶活性测定方法 |
CN104897840A (zh) * | 2015-06-18 | 2015-09-09 | 牡丹江友搏药业股份有限公司 | 一种疏血通注射液中多肽(寡肽)类成分质量控制的新方法 |
-
2016
- 2016-04-29 CN CN201610272887.9A patent/CN105949335B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103592303A (zh) * | 2013-11-25 | 2014-02-19 | 牡丹江友搏药业股份有限公司 | 一种疏血通注射液的抗凝血酶活性测定方法 |
CN104897840A (zh) * | 2015-06-18 | 2015-09-09 | 牡丹江友搏药业股份有限公司 | 一种疏血通注射液中多肽(寡肽)类成分质量控制的新方法 |
Non-Patent Citations (1)
Title |
---|
丁冠华: "水蛭地龙药材商品中总多糖含量测定", 《中华中医药学刊》 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106674367A (zh) * | 2016-12-14 | 2017-05-17 | 烟台东诚药业集团股份有限公司 | 一种纯化制备低聚异麦芽糖的方法以及应用 |
CN109270176A (zh) * | 2018-08-22 | 2019-01-25 | 中国农业科学院农产品加工研究所 | 羊乳寡糖测定方法 |
CN109270176B (zh) * | 2018-08-22 | 2021-10-22 | 中国农业科学院农产品加工研究所 | 羊乳寡糖测定方法 |
WO2022067773A1 (zh) * | 2020-09-30 | 2022-04-07 | 牡丹江友搏药业有限责任公司 | 一种活性多肽及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN105949335B (zh) | 2018-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4692435A (en) | Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation | |
CN107698689B (zh) | 一种从鱼腥草中提取多糖的方法 | |
Lin et al. | A sensitive and specific HPGPC‐FD method for the study of pharmacokinetics and tissue distribution of Radix Ophiopogonis polysaccharide in rats | |
CN105675779B (zh) | 一种定量检测含糖醛酸多糖的方法 | |
CN103884811B (zh) | 一种生物色谱比较筛选系统及其应用 | |
Wang et al. | Screening of anti‐platelet aggregation agents from Panax notoginseng using human platelet extraction and HPLC–DAD–ESI‐MS/MS | |
CN109593141B (zh) | 一种益母草多糖的制备方法及其用途 | |
KR20150001777A (ko) | 징코라이드의 추출 분리 방법 | |
CN109239224B (zh) | 酸枣仁水提物中9种入血成分的同时定量测定方法 | |
CN105949335A (zh) | 一种具有抗血小板聚集活性的寡糖类组分及其制备方法 | |
CN106770865B (zh) | 一种银杏叶提取物中有机酸含量测定方法 | |
CN113201081B (zh) | 具免疫活性的平卧菊三七多糖及其制备方法和应用 | |
CN103724445A (zh) | 灰树花多糖f2的制备方法及其降血糖功能 | |
WO2020093510A1 (zh) | 一种灵芝孢子多糖的分离纯化方法 | |
CN102432620B (zh) | 一种白藜芦醇四聚体化合物及其制备方法和应用 | |
CN107011453A (zh) | 一种维药恰麻古多糖及其提取方法和应用 | |
Liu et al. | Quality markers for processed products of Morinda officinalis how based on the “oligosaccharides-spectrum-effect” | |
CN102464581B (zh) | 一种制备丹参素钠的方法 | |
CN104530253B (zh) | 一种黄精多糖的柱层析分离方法和提取方法 | |
CN110551233B (zh) | 一种广东紫珠多糖及其提取方法和用途 | |
CN103804506B (zh) | 一种从小肠浸出液中提取肝素和硫酸皮肤素的方法 | |
CN110376292A (zh) | 一种人参提取物对照品、制备方法及其应用 | |
CN105687262A (zh) | 一种银杏叶酊剂及其制备方法 | |
CN113861301B (zh) | 一种非淀粉百合多糖nslp-1及其应用 | |
AU686161B2 (en) | Remitting agent for nephrotic syndrome and hepatopathy symptoms |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
CB02 | Change of applicant information |
Address after: 157013 Heilongjiang province Mudanjiang City Yangming District Yumin Road No. 288 Applicant after: MUDANJIANG YOUBO PHARMACEUTICAL Co.,Ltd. Address before: 157011 Heilongjiang province Mudanjiang City Yangming District Yumin Road No. 288 Applicant before: MUDANJIANG YOUBO PHARMACEUTICAL Co.,Ltd. |
|
COR | Change of bibliographic data | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Zhenguo Inventor after: Chen Yanming Inventor after: Zhou Jianbo Inventor after: Xia Ke Inventor after: Guo Yafang Inventor before: Li Zhenguo Inventor before: Chen Yanming Inventor before: Zhou Jianbo Inventor before: Xia Ke |
|
GR01 | Patent grant | ||
GR01 | Patent grant |